The criminal trial against Theranos Founder and former CEO Elizabeth Holmes now focuses on testimony from Safeway, Walgreens, and Johns Hopkins University. Questions involve how these companies evaluated Theranos’ blood-testing technology and concluded that it was sound when, in fact, results was consistently false.

At this point in the trail, investors blame Holmes, whose defense is that the companies did due diligence and are responsible for their decisions. A Wall Street Journal article about the arguments highlights the companies’ and the university’s failings and over-reliance on Holmes’ claims.

As the relationship between Safeway and Theranos progressed, CEO Steve Burd wrote an email to Theranos with the subject, “Becoming Discouraged.” He testified, “I think whenever you start something new you’re going to have some rough spots, but we continued to have rough spots. We had samples that were lost. We had results that didn’t make any sense.”

We’ll see how the trial evolves, but clearly, experts needed to ask more questions up front. In some cases, they didn’t test the actual technology themselves. This story is a good example of failures in integrity and data analysis—perhaps for many involved.